Investment Thesis
Ernexa Therapeutics is a pre-revenue pharmaceutical company with severe operational losses and negative cash flows. Despite a spike in revenue (+756% YoY), absolute sales remain negligible at $582K while operating losses reached $9.3M, indicating the company is burning cash with minimal commercial traction. With only $1.9M in cash and negative free cash flow of $7.1M annually, the company faces critical liquidity constraints within months unless it secures additional financing.
Strengths
- Strong gross margin of 83.5% suggests product pricing power and efficient manufacturing when revenue scales
- Low debt-to-equity ratio of 0.22x indicates minimal leverage and financial flexibility for equity financing
- Revenue growth of 756% YoY demonstrates emerging commercial activity from previous near-zero baseline
Risks
- Severe cash burn of $7.1M in free cash flow with only $1.9M cash on hand creates imminent liquidity crisis
- Massive operating losses and negative margins across all profitability metrics indicate unsustainable business model
- Negligible revenue base of $582K demonstrates lack of commercial product-market fit or meaningful market adoption
- High risk of dilutive financing or equity collapse required to meet operational cash needs
Key Metrics to Watch
- Cash runway and date of next financing requirement
- Quarterly revenue growth trajectory and path to positive gross profit contribution
- Operating expense reduction and timeline to cash flow breakeven
- Clinical development milestones and regulatory approval progress for pipeline assets
Financial Metrics
Revenue
582.0K
Net Income
-14.1M
EPS (Diluted)
$-2.24
Free Cash Flow
-7.1M
Total Assets
5.8M
Cash
1.9M
Profitability Ratios
Gross Margin
83.5%
Operating Margin
-1,601.2%
Net Margin
-2,419.9%
ROE
-586.6%
ROA
-241.4%
FCF Margin
-1,212.0%
Balance Sheet & Liquidity
Current Ratio
1.01x
Quick Ratio
1.01x
Debt/Equity
0.22x
Debt/Assets
58.8%
Interest Coverage
-423.59x
Long-term Debt
532.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T11:26:11.051039 |
Data as of: 2025-12-31 |
Powered by Claude AI